{"disease":{"id":"stage-iv-nsclc","name":"stage iv nsclc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT05701787","title":"Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT04492969","title":"Prospective Observation of Failure Patterns in NSCLC Treated With ICIs","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT06961188","title":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05344209","title":"Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Vestre Viken Hospital Trust","has_results":false},{"nct_id":"NCT04027647","title":"Phase 2 Study of Dacomitinib in NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT06374160","title":"Exercise in Patients With Advanced Non-small Cell Lung Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04245085","title":"ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":false},{"nct_id":"NCT04768491","title":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT05157776","title":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Tongji University","has_results":false},{"nct_id":"NCT06671613","title":"Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT05816499","title":"Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03620669","title":"1st Line Durvalumab in PS 2 NSCLC Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT04636775","title":"Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)","phase":"","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Jun Zhang, MD, PhD","has_results":false},{"nct_id":"NCT04521075","title":"A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Ella Therapeutics Ltd","has_results":false},{"nct_id":"NCT03805841","title":"Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Rain Oncology Inc","has_results":true},{"nct_id":"NCT05988697","title":"Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT06951399","title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT03713944","title":"Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Nasser Hanna","has_results":true},{"nct_id":"NCT04676386","title":"Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy","phase":"","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Addario Lung Cancer Medical Institute","has_results":false},{"nct_id":"NCT03812549","title":"Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Sichuan University","has_results":true},{"nct_id":"NCT05837767","title":"A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04932343","title":"Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05631574","title":"Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Biomea Fusion Inc.","has_results":false},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT03130829","title":"To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Hi-Q Marine Biotech International, Ltd.","has_results":false},{"nct_id":"NCT06064279","title":"Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"VA Office of Research and Development","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}